In short
Recent clinical trials are investigating the use of Olea Europaea Pollen Extract as a potential treatment for individuals suffering from moderate to severe allergic reactions to olive pollen. This article delves into the ongoing research, focusing on a Phase II-III study that aims to assess the efficacy and safety of subcutaneous cluster-immunotherapy using this extract. The study targets patients with allergic rhinitis or rhinoconjunctivitis caused by olive pollen, exploring various dosages to determine the most effective and well-tolerated treatment option.
At a glance
- Study Type
- Phase II-III clinical trial
- Treatment
- Subcutaneous cluster-immunotherapy with Olea Europaea Pollen Extract
- Target Condition
- Moderate to severe allergic rhinitis/rhinoconjunctivitis due to olive pollen
- Primary Endpoint
- Difference in Combined Symptom and Medication Score (CSMS) during Peak Olive Pollen Period
- Key Eligibility Criteria
- Adults 18-65, positive skin prick test and specific IgE to Olea europaea
- Safety Assessment
- Analysis of Treatment-Emergent Adverse Drug Reactions (TEADR)
- Secondary Endpoints
- Quality of life, symptom-free days, nasal provocation test results
What is Olea Europaea Pollen Extract?
Olea Europaea Pollen Extract, also known as olive pollen extract, is a substance derived from olive tree pollen. It is being studied as a potential treatment for people who suffer from allergies to olive pollen. This extract is used in a form of treatment called subcutaneous immunotherapy, which involves injecting small amounts of the allergen under the skin to help the body build tolerance over time.
Medical Condition Treated
The primary medical condition targeted by this treatment is moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by olive pollen. These conditions involve inflammation of the nasal passages (rhinitis) and eyes (conjunctivitis) due to an allergic reaction to olive pollen. Symptoms may include:
- Sneezing
- Runny or stuffy nose
- Itchy or watery eyes
- Itchy nose or throat
The condition must have been present for at least two years, as defined by the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
How It Works
Olea Europaea Pollen Extract is used in a treatment called subcutaneous cluster-immunotherapy. This therapy works by exposing the immune system to small, controlled amounts of the allergen (in this case, olive pollen). Over time, this exposure can help the body build tolerance to the allergen, reducing allergic reactions when naturally exposed to olive pollen.
Clinical Trial Details
A Phase II-III clinical trial is being conducted to assess the efficacy and safety of this treatment. The main objective of the trial is to determine the most effective and best-tolerated dose of the extract. The study will measure the Combined Symptom and Medication Score (CSMS), which takes into account both the severity of allergy symptoms and the amount of medication needed to control them.
Eligibility Criteria
To participate in the clinical trial, patients must meet specific criteria, including:
- Age between 18 and 65 years
- Diagnosed with moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to olive pollen for at least two years
- Positive skin prick test and blood test for olive pollen allergy
- No previous immunotherapy with olive pollen or related allergens in the past 5 years
There are also several exclusion criteria, such as severe asthma, certain immune system disorders, and pregnancy.
Potential Benefits
If successful, this treatment could provide several benefits for patients with olive pollen allergies:
- Reduced allergy symptoms during olive pollen season
- Decreased need for allergy medications
- Improved quality of life during pollen season
- Potential long-term reduction in allergy severity
The clinical trial will measure these outcomes using various methods, including symptom scores, medication use, and quality of life questionnaires.
Safety and Side Effects
As with any medical treatment, there are potential risks and side effects. The clinical trial will closely monitor participants for any adverse reactions. Common side effects of immunotherapy can include:
- Local reactions at the injection site (redness, swelling, itching)
- Mild allergic reactions (sneezing, nasal congestion)
- In rare cases, more severe allergic reactions
The study will analyze the safety and tolerability of each dose compared to a placebo, tracking any Treatment-Emergent Adverse Drug Reactions (TEADRs).